失代偿期肝硬化的肌少症与衰弱
本综述聚焦失代偿期肝硬化患者的肌少症与衰弱,阐述其复杂病理生理机制、与失代偿的关联及评估工具,并强调营养摄入与运动等管理策略,同时指出住院患者测量方法等知识空白。
要点
- 肌少症定义为肌肉量丢失,衰弱为肌肉功能丧失的表型表现。
- 两者与肝硬化患者并发症、死亡、生活质量差及肝移植后不良结局密切相关。
- 管理包括足量热量与蛋白质摄入及至少中等强度有氧加抗阻运动。
核心结论
- 失代偿期肝硬化中肌少症与衰弱常见,与不良结局密切相关,需早期识别与评估。
研究设计与样本
- 综述,未报告系统检索范围与样本量。
主要发现
- 肌少症与衰弱均与肝硬化患者并发症、死亡、生活质量差及肝移植后结局差强相关。
- 综述描述了肌少症与衰弱临床表型背后的复杂病理生理及其与失代偿的关联。
关键数值与推荐
- 肝病领域肌少症常定义为肌肉量丢失,衰弱广义定义为肌肉功能丧失的表型表现。
临床怎么用
- 应早期识别并准确评估肌少症与衰弱,关注住院等急性失代偿患者。
- 管理策略包括足量热量与蛋白质营养摄入,以及至少中等强度有氧与抗阻混合运动。
局限性
- 住院环境下测量肌肉量与功能的最佳方法尚不明确。
- 肌少症与衰弱发生和表现的种族/民族差异尚不清楚。
- 评估治疗反应并转化为减少不良结局的最佳临床指标尚待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with decompensated cirrhosis, sarcopenia and frailty are prevalent. Although several definitions exist for these terms, in the field of hepatology, sarcopenia has commonly been defined as loss of muscle mass, and frailty has been broadly defined as the phenotypic manifestation of the loss of muscle function. Prompt recognition and accurate assessment of these conditions are critical as they are both strongly associated with morbidity, mortality, poor quality of life and worse post-liver transplant outcomes in patients with cirrhosis. In this review, we describe the complex pathophysiology that underlies the clinical phenotypes of sarcopenia and frailty, their association with decompensation, and provide an overview of tools to assess these conditions in patients with cirrhosis. When available, we highlight data focusing on patients with acutely decompensated cirrhosis, such as inpatients, as this is an area of unmet clinical need. Finally, we discuss management strategies to reverse and/or prevent the development of sarcopenia and frailty, which include adequate nutritional intake of calories and protein, as well as regular exercise of at least moderate intensity, with a mix of aerobic and resistance training. Key knowledge gaps in our understanding of sarcopenia and frailty in decompensated cirrhosis remain, including best methods to measure muscle mass and function in the inpatient setting, racial/ethnic variation in the development and presentation of sarcopenia and frailty, and optimal clinical metrics to assess response to therapeutic interventions that translate into a reduction in adverse outcomes associated with these conditions.
引用
- Tandon P, Montano-Loza AJ, Lai JC, et al. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 2021. PMID: 34039486. doi:10.1016/j.jhep.2021.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。